Advertisement

Immunogenetics

, Volume 58, Issue 8, pp 693–699 | Cite as

Evaluation of interleukin 13 polymorphisms in systemic sclerosis

  • Brigitte GranelEmail author
  • Christophe Chevillard
  • Yannick Allanore
  • Violaine Arnaud
  • Sandrine Cabantous
  • Sandrine Marquet
  • Pierre-Jean Weiller
  • Jean-Marc Durand
  • Jean-Robert Harlé
  • Claire Grange
  • Yves Frances
  • Philippe Berbis
  • Jean Gaudart
  • Philippe de Micco
  • André Kahan
  • Alain Dessein
Brief Communication

Abstract

Systemic sclerosis (SSc) is a multisystem disease of unknown etiology. It is characterized by excessive cutaneous and visceral fibrosis, damage to small blood vessels, and production of autoantibodies. Interleukin-13 (IL-13) has been shown to be involved in abnormal fibrosis in other diseases. Therefore, we have evaluated its possible involvement in SSc. We analyzed four IL13 gene polymorphisms, rs1800925 (IL13-1055), rs20541 (Arg130Gln), rs847, and rs2243204 in 107 unrelated SSc patients (40 patients having diffuse cutaneous form and 67 patients having limited cutaneous form) and in 170 controls. All subjects were Caucasians. In the total patient population and in the diffuse cutaneous subset, we observed an association between two IL13 polymorphisms, IL13 rs1800925 (IL13-1055), and IL13 rs2243204, and disease (p=0.03–0.04). The IL13 rs2243204T allele was more common in SSc patients (p=0.01, OR=2.3 CI 1.21–4.38) and in the diffuse cutaneous form (p=0.01, OR=2.95, CI 1.35–6.49) than in control subjects. Our result supports the suggestion that polymorphisms in IL13 are associated to SSc and skin fibrosis process. However, further studies on larger and independent population and functional analyses are needed to confirm these findings.

Keywords

Systemic sclerosis Interleukin-13 IL13 gene Fibrosis Polymorphisms 

Notes

Acknowledgements

We thank Dr Howard Cann for providing the CEPH reference population DNAs. We thank Pascale David, Ruth Zbili and Anne-Marie Dombey, all medical doctors working in the “Etablissement Français du Sang-Alpes-Méditerranée” for providing healthy blood donors samples. This work was financially supported by INSERM, the Association des Sclérodermiques de France (ASF) with the Groupe Français de Recherche sur la Sclérodermie (GFRS) and by the Assistance Publique-Hôpitaux de Marseille (APHM) (AORC 2004).

References

  1. Artlett CM (2005) Immunology of systemic sclerosis. Front Biosci 10:170–719Google Scholar
  2. Assassi S, Tan FK (2005) Genetics of scleroderma: update on single nucleotide polymorphism analysis and microarrays. Curr Opin Rheumatol 17:761–767PubMedCrossRefGoogle Scholar
  3. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA (1999) An IL13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 104:777–785PubMedGoogle Scholar
  4. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, Dayer JM (2003) Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 48:2593–2604PubMedCrossRefGoogle Scholar
  5. Doucet C, BroutyBoye D, PottinClemenceau C, Canonica GW, Jasmin C, Azzarone B (1998a) Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 101:2129–2139PubMedGoogle Scholar
  6. Doucet C, BroutyBoye D, PottinClemenceau C, Jasmin C, Canonica GW, Azzarone B (1998b) IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 10:1421–1433PubMedCrossRefGoogle Scholar
  7. Graves PE, Kabesch M, Halonen M, Holberg CJ, Baldini M, Fritzsch C, Weiland SK, Erickson RP, von Mutius E, Martinez FD (2000) A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J Allergy Clin Immunol 105:506–513PubMedCrossRefGoogle Scholar
  8. Hancock A, Armstrong L, Gama R, Millar A (1998) Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 18:60–65PubMedGoogle Scholar
  9. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin-4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 26:328–332Google Scholar
  10. Hummelshoj T, Bodtger U, Datta P, Malling HJ, Oturai A, Poulsen LK, Ryder LP, Sorensen PS, Svejgaard E, Svejgaard A (2003) Association between an interleukin-13 promoter polymorphism and atopy. Eur J Immunogenet 30:355–359PubMedCrossRefGoogle Scholar
  11. Johnson RW, Tew MB, Arnett FC (2002) The genetics of systemic sclerosis. Curr Rheumatol Rep 4:99–107PubMedGoogle Scholar
  12. Kissin EY, Korn JH (2003) Fibrosis in scleroderma. Rheum Dis Clin North Am 29:351–369PubMedCrossRefGoogle Scholar
  13. Kouriba B, Chevillard C, Bream JH, Argiro L, Dessein H, Arnaud V, Sangare L, Dabo A, Beavogui AH, Arama C, Traore HA, Doumbo O, Dessein A (2005) Analysis of the 5q31–q33 locus shows an association between IL13-1055C/T IL-13-591A/G polymorphisms and Schistosoma haematobium infections. J Immunol 174:6274–6281PubMedGoogle Scholar
  14. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA (2001) Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 194:809–821PubMedCrossRefGoogle Scholar
  15. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMedGoogle Scholar
  16. Liu X, Nickel R, Beyer K, Wahn U, Ehrlich E, Freidhoff LR, Bjorksten B, Beaty TH, Huang SK (2000) An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German multicenter atopy study (MAS-90). J Allergy Clin Immunol 106:167–170PubMedCrossRefGoogle Scholar
  17. Ma B, Zhu Z, Homer RJ, Gerard C, Strieter R, Elias JA (2004) The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 172:1872–1881PubMedGoogle Scholar
  18. Matsushita M, Yamamoto T, Nishioka K (2004) Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int Arch Allergy Immunol 135:348–356PubMedCrossRefGoogle Scholar
  19. Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M (2001) Interleukin-13 and interleukin-13 receptor in Hodgkin’s disease: possible autocrine mechanism and involvement in fibrosis. Histopathology 38:368–375PubMedCrossRefGoogle Scholar
  20. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM (2000) Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 292:988–994PubMedGoogle Scholar
  21. Riccieri V, Rinaldi T, Spadaro A, Scrivo R, Ceccarelli F, Franco MD, Taccari E, Valesini G (2003) Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol 22:102–106PubMedCrossRefGoogle Scholar
  22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnosis and Therapeutic Criteria Committee (1980) Arthritis Rheum 23:581–590Google Scholar
  23. Tolusso B, Fabris M, Caporali R, Cuomo G, Isola M, Soldano F, Montecucco C, Valentini G, Ferraccioli G (2005) −238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. Immunol Lett 96:103–108PubMedCrossRefGoogle Scholar
  24. van der Pouw Kraan TC, van Veen A, Boeije LC, van Tuyl SA, de Groot ER, Stapel SO, Bakker A, Verweij CL, Aarden LA, van der Zee JS (1999) An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun 1:61–65PubMedCrossRefGoogle Scholar
  25. van der Pouw Kraan TC, Kucukaycan M, Bakker AM, Baggen JM, van der Zee JS, Dentener MA, Wouters EF, Verweij CL (2002) Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism. Genes Immun 3:436–439PubMedCrossRefGoogle Scholar
  26. Wills-Karp M, Chiaramonte M (2003) Interleukin-13 in asthma. Curr Opin Pulm Med 9:217CrossRefGoogle Scholar
  27. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA (1999) Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 103:779–788PubMedCrossRefGoogle Scholar
  28. Zhu Z, Ma B, Zheng T, Homer RJ, Lee CG, Charo IF, Noble P, Elias JA (2002) IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 168:2953–2962PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Brigitte Granel
    • 1
    • 2
    • 10
    Email author
  • Christophe Chevillard
    • 1
  • Yannick Allanore
    • 3
    • 11
  • Violaine Arnaud
    • 1
  • Sandrine Cabantous
    • 1
  • Sandrine Marquet
    • 1
  • Pierre-Jean Weiller
    • 4
  • Jean-Marc Durand
    • 5
  • Jean-Robert Harlé
    • 5
  • Claire Grange
    • 6
  • Yves Frances
    • 2
  • Philippe Berbis
    • 7
  • Jean Gaudart
    • 8
  • Philippe de Micco
    • 9
  • André Kahan
    • 3
  • Alain Dessein
    • 1
  1. 1.Laboratoire d’Immunologie et de Génétique des Maladies Parasitaires, UMR 399 INSERMUniversité de la Méditerranée, Faculté de MédecineMarseilleFrance
  2. 2.Service de Médecine Interne, Hôpital Nord, AP-HMUniversité de la MéditerranéeMarseilleFrance
  3. 3.Service de Rhumatologie A, Faculté de Médecine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP)Université Paris DescarteParisFrance
  4. 4.Service de Médecine Interne, Hôpital de La Timone,Assistance Publique-Hôpitaux de Marseille (AP-HM)Université de la MéditerranéeMarseilleFrance
  5. 5.Service de Médecine InterneHôpital de La Conception, AP-HMMarseilleFrance
  6. 6.Service de Médecine InterneCentre Hospitalier Lyon-SudPierre-BeniteFrance
  7. 7.Service de Dermatologie, Hôpital Nord, AP-HMUniversité de la MéditerranéeMarseilleFrance
  8. 8.Equipe Bio-Mathématiques et Informatique MédicaleLIF-UMR 6166-CNRS/Université de la Méditerranée, Faculté de MédecineMarseilleFrance
  9. 9.Site MarseilleEFS-Alpes-MéditerranéeMarseilleFrance
  10. 10.Laboratoire d’Immunologie et de Génétique des Maladies Parasitaires, UMR 399 INSERMUniversité de la Méditerranée, Faculté de Médecine de La TimoneMarseilleFrance
  11. 11.INSERM U781Hopital NeckerParisFrance

Personalised recommendations